Skip to main content

Month: June 2025

Form 8.3 – [GLOBALDATA PLC – 09 06 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree GLOBALDATA PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Form 8.3 – [CRANEWARE PLC – 09 06 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree CRANEWARE PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Form 8.3 – [ALPHA GROUP INTERNATIONAL PLC – 09 06 2025] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ALPHA GROUP INTERNATIONAL PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium (SMC) acceptance of LYTENAVA™ (bevacizumab gamma) for use within NHS Scotland for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the United Kingdom (UK) and has an initial 10 years of market exclusivity from the date of initial marketing authorization from the Medicines and Healthcare products Regulatory Agency. “Receiving the SMC recommendation of LYTENAVA™ (bevacizumab gamma) for patients with...

Continue reading

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced presentations at the American Diabetes Association’s (ADA) 85th Scientific Sessions, taking place June 20-23. 2025, Chicago, IL.846-P – Safety, Pharmacokinetics, and Pharmacodynamics of MBX 1416, a Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers: A Phase 1 Randomized TrialPresenter: Elisa Fabbrini, MD. PhD. Session: General Poster SessionDate: Sunday June 22nd, 2025 Time 12:30-1:30pm CT 845-P – MBX 1416, a Selective GLP-1 Antagonist, Elevates and Sustains Blood Glucose in Rats without Change in Body WeightPresenter: Richard...

Continue reading

Provident Bank Expands Newark Presence with New Branch, Reinforces Commitment to Local Community

New location marks Provident’s fourth branch in Newark and continued commitment to the cityGreater Life Check PresentationLeft to Right: Maria Westbrook, Co-Founder/VP of Administration & Finance, Greater Life; Chanel Mainor, Fund Development, Greater Life; Israel Morales, VP, Banking Center Manager, Provident Bank; Chris Martin, Executive Chairman, Provident BankSt. Johns Soup Kitchen PhotoLeft to Right: Jorge Fernandes, FVP, Market Sales Manager, Provident Bank; Barbara Cury, Executive Director of Social Services, St. Johns Soup Kitchen; Israel Morales, VP, Banking Center Manager, Provident Bank; Chris Martin, Executive Chairman, Provident BankRibbon Cutting PhotoLeft to Right: Michael J. Silva, Councilman, East Ward, City of Newark; Jacqueline Quiles, Deputy Mayor, City of Newark; Jim Kirkos, President...

Continue reading

Alignment Healthcare Founder and CEO John Kao Named to AHIP Board

ORANGE, Calif., June 10, 2025 (GLOBE NEWSWIRE) — Alignment Healthcare, Inc. (NASDAQ: ALHC) announced today that founder and CEO John Kao was elected to the AHIP board of directors, effective June 5, 2025. AHIP is a national business organization whose member companies provide health care coverage, services and solutions to millions of Americans every day. “I’m honored to join the AHIP board and collaborate with leaders across the industry who are committed to making health care work better for more Americans,” said Kao. “The industry is at a critical inflection point, and I look forward to working with my fellow board members to help shape a stronger, more sustainable future for everyone.” “We are very pleased to welcome John to the AHIP board of directors. His experience and vision for a patient-centered, compassionate,...

Continue reading

BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego

Deep TMS Takes Center Stage with Compelling Research BURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, proudly announces its Gold Sponsorship of the Clinical TMS Society’s 2025 Annual Meeting, taking place June 12–14 in San Diego, CA. BrainsWay’s participation will spotlight its industry-leading Deep Transcranial Magnetic Stimulation (Deep TMS™) technology, including live demonstrations and groundbreaking new research that continues to set Deep TMS apart. Clinical Education Session – Saturday, June 14 | 7:00 – 8:00 AM BrainsWay will host a sponsored morning session titled, “Accelerating Relief: Multicenter RCT Results from a Novel H1 Coil Accelerated Deep TMS Depression...

Continue reading

DeepView® System highlighted at the annual British Burn Association conference

DALLAS, June 10, 2025 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the annual British Burn Association (BBA) conference, held from June 4th – 6th in Brighton, UK. The Company was featured in multiple presentations, highlighting its contributions to advancing burn care across the globe. Key Presentations at BBA:The First Reader Study of Burn Wounds with Predictive Artificial Intelligence Analysis – Dr. Jeffrey Carter, M.D., Louisiana State University Health Science Center Artificial Intelligence-Enhanced Multispectral Imaging for Burn Wound Assessment: Insights from a Multi-Centre UK Trial – Leslie Poh Hong Tan, Royal...

Continue reading

Oxford Lane Capital Corp. Provides May 2025 Net Asset Value Update

GREENWICH, Conn., June 10, 2025 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) (NasdaqGS: OXLCG) (the “Company”) today announced the following net asset value (“NAV”) estimate as of May 31, 2025.Management’s unaudited estimate of the range of the NAV per share of our common stock as of May 31, 2025, is between $4.17 and $4.27. This estimate is not a comprehensive statement of our financial condition or results for the month ended May 31, 2025. This estimate did not undergo the Company’s typical quarter-end financial closing procedures and was not approved by the Company’s board of directors. We advise you that our NAV per share for the quarter ending June 30, 2025 may differ materially from this estimate,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.